Hepatitis B virus resistance to tenofovir: fact or fiction? 2 A synthesis of the evidence to date

48 Background: Tenofovir (TFV) is a widely used antiviral treatment for chronic hepatitis B virus 49 (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated 50 mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well 51 understood, and the topic remains contentious. We here present assimilated evidence for 52 putative TFV RAMs with the aims of cataloguing and characterising mutations that have been 53 reported, and starting to develop insights into the mechanisms of resistance and potential 54 clinical significance. 55 Methods: We carried out a systematic literature search in PubMed to identify clinical, in vitro 56 and in silico evidence of TFV resistance. The structure of HBV reverse transcriptase (RT) has 57 not been solved; we therefore compared HBV RT to the crystal structure for HIV RT to map 58 the likely sites of RAMs. 59 Results: We identified a ‘long-list’ of 37 putative TFV RAMs in HBV RT, occurring within and 60 outside sites of enzyme activity, some of which can be mapped onto a homologous HIV RT 61 structure. Based on quality and quantity of supporting data, we generated a ‘short-list’ of nine 62 sites that are supported by the most robust evidence. Most resistance arises as a result of 63 suites of multiple RAMs. Other factors including adherence, viral load, HBeAg status, HIV 64 coinfection and NA dosage may also influence viraemic suppression. 65 Conclusion: There is emerging evidence for polymorphisms that may reduce susceptibility to 66 TVF . A better understanding of HBV drug resistance is imperative to optimise approaches to 67 public health elimination targets.


93
There is some degree of homology between the sequence, structure and function of HIV and 94 HBV RT enzymes, explaining why certain NAs are active against both viruses (9). Although 95 no crystal structure has been resolved for HBV RT, some studies have modelled this enzyme 96 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint 5 based on the HIV crystal structure (9-11), suggesting that insights into HBV drug resistance 97 mechanisms might be inferred from what is known about HIV.

99
A better understanding of the role of NA therapy in driving HBV elimination at a population 100 level is crucial to underpin efforts to move towards international targets for elimination by the . In order to progress towards these targets, many more 105 people will need to be treated in the decade ahead.

107
We have therefore undertaken a systematic approach to assimilate the current evidence for 108 the development of clinical or virological HBV breakthrough during TFV therapy. The evidence 109 on this topic is not currently sufficiently advanced to underpin definitive conclusions regarding 110 specific genetic signatures that underpin TVF resistance, or the extent to which these are 111 significant in clinical practice. However, we add to the field by providing a comprehensive 112 summary of relevant publications, together with a quality appraisal of the evidence. We used 113 this process to assimilata a 'long-list' (all putative TFV RAMs) and a 'short-list' (a refined 114 catalogue containing only the polymorphisms most robustly supported by existing data). We 115 highlight gaps in the existing data and the urgent need for more research.

METHODS 118
Search strategy and quality appraisal

119
We undertook a systematic search of PubMed and Scopus in February 2019, using PRISMA 120 criteria (Suppl Fig 2)

152
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.

166
Among the case reports, three were of high quality as they clearly described patients'    CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint We narrowed the list of 37 sites down to compile a 'short-list' of TFV RAMs that have been 208 identified in ≥2 studies, regarding these sites as having the strongest evidence base (9 sites; 209 Table 1 Table 4). The same phenomenon has been described for HCV 229 resistance, in which certain sub genotypes are predicted to be intrinsically resistant to certain 230 direct acting antiviral agents due to the presence of resistance associated polymorphisms in 231 the wild type sequence (34,35).

233
One study assessed the replication competence and susceptibility to TFV of mutated HBV 234 clones in vitro and in vivo using mice models. The introduction of P177G and F249A mutations 235 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.     CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint sequence (Fig 2). Comparing sites that have been reported in association with drug resistance 264 in HBV vs HIV (Fig 3, Suppl Table 5 Table 6). The RAMs are primarily located within the 'fingers',

330
Resistance to TFV can be explained by RAMs both within and outside the active site of the 331 RT enzyme, some of which may have similar mechanisms to those described in HIV (9,36).

332
The mechanism of resistance in most of these polymorphisms remains unknown, but may

341
Currently, HBV genotyping is not routinely undertaken in clinical practice, so it is difficult to 342 amass data for any potential relationship between resistance and viral genotype. However,

343
there are some clues that genotype may be relevant. For example, C256S has been linked to 344 TFV resistance, but S256 is wild type in genotype C, (Suppl Table 4), suggesting that the 345 genetic barrier to TFV resistance in genotype C might be lower than in other genotypes.

346
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint However, a study of >1000 individuals in China found no differences in drug resistance rates 347 between Geno-B vs Geno-C infection (40). The identification of Y9H as a TFV RAM should 348 be viewed with caution as H9 is frequently the wildtype residue, irrespective of genotype.   CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.     CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint

430
We have assimilated emerging evidence for HBV polymorphisms that reduce susceptibility to 431 TFV, also acknowledging the potential influences of other viral and host factors in cases of 432 persistent viraemia on therapy. While the genetic barrier to resistance is high, evidenced by 433 the large number of mutations that typically have to be selected to produce resistance, of 434 concern is the overlap with other NA resistance mutations, and the instances in which 435 individual amino acid polymorphisms may be sufficient to produce phenotypic resistance.

486
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.

541
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.

569
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020.               CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted April 23, 2020. . https://doi.org/10.1101/19009563 doi: medRxiv preprint